Hikma Pharmaceuticals PLC (FRA:H5P)

Germany flag Germany · Delayed Price · Currency is EUR
18.30
+0.20 (1.10%)
At close: Dec 5, 2025
-22.46%
Market Cap 4.04B
Revenue (ttm) 2.74B
Net Income (ttm) 315.91M
Shares Out n/a
EPS (ttm) 1.42
PE Ratio 12.80
Forward PE 9.22
Dividend 0.75 (4.13%)
Ex-Dividend Date Aug 14, 2025
Volume n/a
Average Volume 2
Open 18.30
Previous Close 18.10
Day's Range 18.30 - 18.30
52-Week Range 17.50 - 28.40
Beta n/a
RSI 47.15
Earnings Date Nov 21, 2025

About Hikma Pharmaceuticals

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic and specialty injectable products primarily for use in hospitals. The Generics segment offers oral, respiratory, and other generic and specialty products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company... [Read more]

Industry Pharmaceutical Preparations
Founded 1978
Employees 9,500
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol H5P
Full Company Profile

Financial Performance

In 2024, Hikma Pharmaceuticals's revenue was $3.13 billion, an increase of 8.77% compared to the previous year's $2.88 billion. Earnings were $359.00 million, an increase of 88.95%.

Financial numbers in USD Financial Statements

News

There is no news available yet.